5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine
|
- ₹0
- Product name: 5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine
- CAS: 1184971-51-4
- MF: C11H10BrN5
- MW: 292.14
- EINECS:
- MDL Number:
- Synonyms:5-bromo-N-(4,4,5,5-tetradeuterio-1H-imidazol-2-yl)quinoxalin-6-amine;5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl-4,4,5,5-d4)quinoxalin-6-amine
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
storage temp. :Store at -20°C
solubility :DMSO: soluble; Water: 1.5 mg/ml
form :A solid
solubility :DMSO: soluble; Water: 1.5 mg/ml
form :A solid
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|
Description
Brimonidine-d4 is intended for use as an internal standard for the quantification of brimonidine by GC- or LC-MS. Brimonidine is an agonist of α2-adrenergic receptors (α2-ARs; Kis = 2.7, 52, and 44 nM for α2A, α2B, and α2C-ARs, respectively, in CHO cells).1 It is selective for α2-ARs over α1-ARs (Ki = 1,800 nM in human brain). Brimonidine lowers intraocular pressure in DBA/2J mice, a model of glaucoma, to control levels when applied topically to the eye as a 0.1% solution.2 It also inhibits glutamate release, prevents upregulation of NMDA receptors containing NR1 and NR2A subunits, and protects rat retinal ganglion cells against glutamate excitotoxicity in a rat model of retinal ischemia when administered at a dose of 1 mg/kg per day.3 Formulations containing brimonidine have been used in the treatment of open-angle glaucoma and ocular hypertension.More related product prices
BriMonidine-2,3-dione N-(4,5-Dihydro-1H-iMidazol-2-yl)-6-quinoxalinaMine Brimonidine D-tartrate BrimonidineRelated product price
- Brimonidine D-tartrate
₹20643.28 - Brimonidine
₹7999.68-94199.15